

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



IMPACT Therapeutics, Inc
南京英派藥業股份有限公司

(A joint stock company established in the People's Republic of China with limited liability)

(Stock Code: 7630)

VOLUNTARY ANNOUNCEMENT

**ABSTRACT OF MULTIPLE RESEARCH RESULTS ACCEPTED FOR
POSTER PRESENTATION AT 2026 ESMO CONGRESS**

This announcement is made by IMPACT Therapeutics, Inc (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the Company’s shareholders and potential investors about the latest business update of the Group.

The Company is pleased to announce that the latest clinical data for three key pipeline programs, namely senaparib (IMP4297), IMP1734 (also known as EIK1003) and IMP1707 (also known as EIK1004), have been accepted for poster presentation at the 2026 European Society for Medical Oncology (ESMO) Congress. The accepted data comprise: (i) updated Progression-Free Survival (PFS) data from the Phase 3 FLAMES study of senaparib as first-line maintenance therapy of advanced ovarian cancer; (ii) updated data from multiple cohorts of ongoing Phase I/II studies of IMP1734, covering monotherapy, combination therapy with paclitaxel for advanced solid tumors, and combination therapy with abiraterone for metastatic prostate cancer; and (iii) initial results from the first-in-human Phase I/II study of IMP1707, a CNS-penetrant selective PARP1 inhibitor, in patients with HRR-mutated advanced solid tumors.

The European Society for Medical Oncology (ESMO) Congress is one of the most influential academic conferences in the field of oncology globally, and this year’s conference will be held in Madrid, Spain from October 23 to 27, 2026.

SET OUT BELOW IS THE KEY INFORMATION PRESENTED BY THE COMPANY AT THE ESMO CONGRESS:

Senaparib (IMP4297)

Title: Updated Progression-Free Survival (PFS) Results from the FLAMES Study: First-Line Maintenance Senaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer (aOC)

IMP1734

Title: Phase I/II study of a PARP1-selective inhibitor, EIK1003, in combination with abiraterone in patients with metastatic prostate cancer (mPC)

Title: Phase I/II study of a PARP1-selective inhibitor, EIK1003, as monotherapy and in combination with paclitaxel (PTX) in advanced solid tumors

IMP1707

Title: A first-in-human Phase I/II study of EIK1004, a PARP1-selective CNS-penetrant inhibitor, in patients with advanced solid tumors with HRR mutations

ABOUT SENAPARIB (IMP4297)

Senaparib (派舒寧®) is a novel, highly potent PARP1/2 inhibitor independently developed by the Company. Its unique molecular structure ensures excellent target selectivity and a wide safety window. Senaparib capsules received National Medical Products Administration of China (NMPA) approval in January 2025 as a first-line maintenance therapy for adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer achieving complete or partial response to platinum-based chemotherapy, and has been subsequently included in the National Reimbursement Drug List (NRDL) in December 2025. The Company is actively advancing the clinical and regulatory development of senaparib globally. Its Marketing Authorisation Application (MAA) in Europe was formally accepted by the European Medicines Agency (EMA) in August 2025, with approval expected in the second half of 2026. Concurrently, the Company is pursuing life cycle management for senaparib, exploring combination therapy opportunities, and expanding into multiple indications.

ABOUT IMP1734

IMP1734 is a novel PARP1-selective inhibitor with high potency of inhibiting PARP1 and low activity of inhibiting PARP2. Preclinical in vivo models demonstrated high anti-tumor activities and a wide therapeutic window. The improved therapeutic index of IMP1734 over currently marketed non-selective PARP1/2 inhibitors supports its development as monotherapy and in combination with other agents. Overall, Phase I studies demonstrated relatively low rates of hematologic toxicity, and clinical activity was observed at most doses tested, as evidenced by target lesion size reduction and durable responses. In addition, tolerability and efficacy are being evaluated in combination with Abiraterone and Paclitaxel, respectively.

ABOUT IMP1707

IMP1707 is a novel PARP1-selective inhibitor with high potency in inhibiting PARP1 and low activity against PARP2, designed to penetrate the blood-brain barrier. Preclinical in vivo models demonstrated robust anti-tumor activities (complete tumor regression) and favorable brain penetration. IMP1707 is currently under investigation as monotherapy in an ongoing global Phase I/II clinical trial, with preliminary evidence of clinical activity observed in a molecularly selected patient population.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that it will be able to fully realize the potential of senaparib and successfully advance its development for additional indications or develop, or ultimately market, IMP1734 (EIK1003) and IMP1707 (EIK1004). Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
IMPACT Therapeutics, Inc
南京英派藥業股份有限公司
Dr. Sui Xiong CAI
Executive Director and Chief Executive Officer

Hong Kong, July 20, 2026

As at the date of this announcement, the Board comprises (i) Dr. Sui Xiong CAI, Dr. Ye Edward TIAN and Ms. Ning MA as executive Directors; (ii) Dr. Cong XU, Dr. Qiang XU and Mr. Tao LIU as non-executive Directors; and (iii) Dr. Edward Ming GUO, Mr. Chi Hung SIU and Dr. Liming SHAO as independent non-executive Directors.